{"id":3728,"date":"2026-10-09T14:46:16","date_gmt":"2026-10-09T14:46:16","guid":{"rendered":"https:\/\/nhdbio.com\/?p=3728"},"modified":"2026-10-10T07:26:16","modified_gmt":"2026-10-10T07:26:16","slug":"cagrisema-tirzepatide-reimaginer5-explique-en-face-a-face","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/","title":{"rendered":"CagriSema vs tirz\u00e9patide : qu'a r\u00e9ellement compar\u00e9 REIMAGINE 5 ?"},"content":{"rendered":"<p>Un titre affirme qu'un traitement a produit plus de perte de poids qu'un autre. Avant de le d\u00e9clarer gagnant, posez une question plus simple : qui a particip\u00e9, et qu'a-t-on compar\u00e9 exactement ?<\/p>\n<p>L'annonce REIMAGINE 2026 de septembre 5 est utile car les deux traitements ont \u00e9t\u00e9 compar\u00e9s dans le m\u00eame essai. Mais le r\u00e9sultat appartient toujours aux groupes et aux doses test\u00e9s.<\/p>\n<h2>Le r\u00e9sultat, avec son contexte<\/h2>\n<p>Novo Nordisk a annonc\u00e9 ces r\u00e9sultats pr\u00e9liminaires le 21 septembre 2026. REIMAGINE 5 a inclus des adultes atteints de diab\u00e8te de type 2 insuffisamment contr\u00f4l\u00e9 par la metformine, un inhibiteur de SGLT2, ou les deux. L'essai a compar\u00e9 CagriSema 1.0 mg\/1.0 mg au tirz\u00e9patide 5 mg sur 60 semaines.<\/p>\n<table>\n<thead>\n<tr>\n<th>Variation rapport\u00e9e \u00e0 60 semaines<\/th>\n<th>CagriSema<\/th>\n<th>Tirz\u00e9patide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>R\u00e9duction du poids corporel, estimande d'efficacit\u00e9<\/td>\n<td>12.4%<\/td>\n<td>9.1%<\/td>\n<\/tr>\n<tr>\n<td>R\u00e9duction de l'HbA1c<\/td>\n<td>1.71 points de pourcentage<\/td>\n<td>1.67 points de pourcentage<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>La soci\u00e9t\u00e9 a rapport\u00e9 une r\u00e9duction de poids plus importante avec CagriSema et une non-inf\u00e9riorit\u00e9 pour la r\u00e9duction de l'HbA1c. La non-inf\u00e9riorit\u00e9 n'est pas une affirmation de sup\u00e9riorit\u00e9 du contr\u00f4le glyc\u00e9mique. CagriSema associe le cagrilintide et le s\u00e9maglutide et \u00e9tait \u00e0 l'\u00e9tat exp\u00e9rimental dans cette annonce.<\/p>\n<h2>Que signifie une diff\u00e9rence de 3.3 point ?<\/h2>\n<p>Subtracting 9.1 from 12.4 gives 3.3 percentage points. Calling that \u201c3.3% more effective\u201d would leave the reader unsure what the percentage refers to.<\/p>\n<p>\u00c0 titre d'illustration arithm\u00e9tique, si deux personnes hypoth\u00e9tiques commen\u00e7aient chacune \u00e0 100 kg, des r\u00e9ductions de 12.4% et 9.1% \u00e9quivaudraient \u00e0 12.4 kg et 9.1 kg. Ces poids de d\u00e9part sont fictifs et servent \u00e0 expliquer le calcul ; il ne s'agit pas de r\u00e9sultats individuels d'essais ni de pr\u00e9dictions.<\/p>\n<h2>Pourquoi les doses test\u00e9es comptent<\/h2>\n<p>Cette comparaison ne couvre pas toutes les doses possibles de l'un ou l'autre traitement. Elle n'\u00e9tablit pas non plus le r\u00e9sultat chez les personnes sans diab\u00e8te. Un titre prudent nomme l'essai plut\u00f4t que de d\u00e9clarer un vainqueur universel.<\/p>\n<p>Pensez \u00e0 la comparaison de deux voitures sur un m\u00eame trajet. Le test peut vous dire ce qui s'est pass\u00e9 sur ce trajet, dans ces conditions. Il ne peut pas r\u00e9pondre \u00e0 toutes les questions sur toutes les routes.<\/p>\n<h2>Le poids et la glyc\u00e9mie sont des crit\u00e8res distincts<\/h2>\n<p>HbA1c est une mesure d'analyse sanguine utilis\u00e9e pour \u00e9valuer les niveaux de glucose \u00e0 plus long terme. Le poids corporel mesure autre chose. Un meilleur r\u00e9sultat sur un crit\u00e8re ne signifie pas automatiquement un meilleur r\u00e9sultat sur l'autre.<\/p>\n<p>De m\u00eame, l'estimande d'efficacit\u00e9 d\u00e9crit une mani\u00e8re particuli\u00e8re d'estimer l'effet du traitement. Il doit rester associ\u00e9 au chiffre de poids lorsque ce nombre est cit\u00e9. L'omettre rend les comparaisons avec des \u00e9tudes analys\u00e9es diff\u00e9remment plus difficiles \u00e0 interpr\u00e9ter.<\/p>\n<h2>Que devraient rechercher les lecteurs ensuite ?<\/h2>\n<p>Les actualit\u00e9s de premier plan donnent un premier aper\u00e7u. Un rapport d\u00e9taill\u00e9 devrait permettre aux lecteurs d\u2019examiner le nombre de participants, les r\u00e9sultats manquants, l\u2019incertitude, les arr\u00eats de traitement et les \u00e9v\u00e9nements ind\u00e9sirables. Ces d\u00e9tails sont n\u00e9cessaires avant de transformer deux pourcentages en un jugement plus large sur le b\u00e9n\u00e9fice et la tol\u00e9rance.<\/p>\n<h2>Documents associ\u00e9s pour la recherche en laboratoire<\/h2>\n<p>Le <a href=\"https:\/\/nhdbio.com\/fr\/produits\/cagrilintide\/\">Cagrilintide<\/a> et <a href=\"https:\/\/nhdbio.com\/fr\/produits\/tirzepatide\/\">Tirz\u00e9patide<\/a> les pages identifient les familles de catalogues associ\u00e9es. NHD liste aussi une <a href=\"https:\/\/nhdbio.com\/fr\/produits\/melange-de-cagrilintide-et-de-seaglutide\/\">Cagrilintide\u2013Semaglutide blend<\/a>; cette inscription ne prouve pas qu\u2019il reproduit le m\u00e9dicament de l\u2019essai ni sa formulation.<\/p>\n<p>Pour une demande de renseignements, indiquez-nous le nom du mat\u00e9riel, la quantit\u00e9 et le test de laboratoire pr\u00e9vu. Demandez quels dossiers d\u2019identit\u00e9, de puret\u00e9 et d\u2019autres dossiers analytiques sont disponibles pour la variante s\u00e9lectionn\u00e9e. <a href=\"https:\/\/nhdbio.com\/fr\/citation\/\">Demander des informations sur le produit aupr\u00e8s de NHD<\/a>.<\/p>\n<p>Les m\u00e9dicaments utilis\u00e9s dans ces essais ne sont pas interchangeables avec les mat\u00e9riaux de catalogue NHD. Les r\u00e9sultats des essais n'\u00e9tablissent pas d'effets cliniques, d'\u00e9quivalence de formulation ni la qualit\u00e9 d'un lot NHD.<\/p>\n<h2>En savoir plus<\/h2>\n<p><a href=\"https:\/\/nhdbio.com\/fr\/cagrisema-redefinit1-changement-de-poids-combinaison-expliquee\/\">Explorer l'explication de recherche associ\u00e9e<\/a>.<\/p>\n<h2>Source et r\u00e9vision \u00e9ditoriale<\/h2>\n<p><a href=\"https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=916774\">Annonce de Novo Nordisk, 21 septembre 2026<\/a>. Consult\u00e9 le 9 octobre 2026. Cet article explique une annonce d'entreprise ; il ne s'agit pas d'une \u00e9valuation par les pairs ind\u00e9pendante. Des v\u00e9rifications assist\u00e9es par IA des sources et de la lisibilit\u00e9 ont \u00e9t\u00e9 effectu\u00e9es avant publication.<\/p>\n<p>Les mat\u00e9riaux de catalogue NHD sont destin\u00e9s \u00e0 la recherche en laboratoire, au d\u00e9veloppement et \u00e0 la fabrication, et non \u00e0 un usage humain ou v\u00e9t\u00e9rinaire. Cet article ne fournit aucune instruction de traitement ou de dosage.<\/p>","protected":false},"excerpt":{"rendered":"<p>L'annonce REIMAGINE de septembre 2026 5 a rapport\u00e9 une r\u00e9duction de poids de 12.4% contre 9.1%. Comprenez la population, les doses test\u00e9es et les limites de la comparaison.<\/p>","protected":false},"author":1,"featured_media":3925,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"320,321,370","pim_article_type":"Research news explained","pim_evidence_level":"Company-reported results; study-specific limitations retained","pim_reviewer":"Codex AI editorial","pim_reviewed_date":"2026-10-09","pim_editorial_note":"AI-assisted source and readability checks, not independent peer review.","pim_review_status":"reviewed","pim_review_reason":"Primary sources and corrections checked; study populations and limitations retained; product-family links and enquiry paths reviewed; plain-language edit completed.","pim_creation_method":"AI-assisted writing","pim_sources":"[]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-3728","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?<\/title>\n<meta name=\"description\" content=\"The September 2026 REIMAGINE 5 announcement reported 12.4% versus 9.1% weight reduction. Understand the population, tested doses and limits of the comparison.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/cagrisema-tirzepatide-reimaginer5-explique-en-face-a-face\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?\" \/>\n<meta property=\"og:description\" content=\"The September 2026 REIMAGINE 5 announcement reported 12.4% versus 9.1% weight reduction. Understand the population, tested doses and limits of the comparison.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/cagrisema-tirzepatide-reimaginer5-explique-en-face-a-face\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-09T14:46:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-10T07:26:16+00:00\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?\",\"datePublished\":\"2026-10-09T14:46:16+00:00\",\"dateModified\":\"2026-10-10T07:26:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/\"},\"wordCount\":562,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-3728.jpg\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/\",\"name\":\"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-3728.jpg\",\"datePublished\":\"2026-10-09T14:46:16+00:00\",\"dateModified\":\"2026-10-10T07:26:16+00:00\",\"description\":\"The September 2026 REIMAGINE 5 announcement reported 12.4% versus 9.1% weight reduction. Understand the population, tested doses and limits of the comparison.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-3728.jpg\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/nhd-comic-3728.jpg\",\"width\":1536,\"height\":1024,\"caption\":\"Editorial comic illustration: CagriSema vs Tirzepatide. Conceptual cover, not experimental imagery.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CagriSema vs tirz\u00e9patide : qu'a r\u00e9ellement compar\u00e9 REIMAGINE 5 ?","description":"L'annonce REIMAGINE de septembre 2026 5 a rapport\u00e9 une r\u00e9duction de poids de 12.4% contre 9.1%. Comprenez la population, les doses test\u00e9es et les limites de la comparaison.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/cagrisema-tirzepatide-reimaginer5-explique-en-face-a-face\/","og_locale":"fr_FR","og_type":"article","og_title":"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?","og_description":"The September 2026 REIMAGINE 5 announcement reported 12.4% versus 9.1% weight reduction. Understand the population, tested doses and limits of the comparison.","og_url":"https:\/\/nhdbio.com\/fr\/cagrisema-tirzepatide-reimaginer5-explique-en-face-a-face\/","og_site_name":"NHD","article_published_time":"2026-10-09T14:46:16+00:00","article_modified_time":"2026-10-10T07:26:16+00:00","author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?","datePublished":"2026-10-09T14:46:16+00:00","dateModified":"2026-10-10T07:26:16+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/"},"wordCount":562,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-3728.jpg","articleSection":["Published Study Reviews"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/","url":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/","name":"CagriSema vs tirz\u00e9patide : qu'a r\u00e9ellement compar\u00e9 REIMAGINE 5 ?","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-3728.jpg","datePublished":"2026-10-09T14:46:16+00:00","dateModified":"2026-10-10T07:26:16+00:00","description":"L'annonce REIMAGINE de septembre 2026 5 a rapport\u00e9 une r\u00e9duction de poids de 12.4% contre 9.1%. Comprenez la population, les doses test\u00e9es et les limites de la comparaison.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-3728.jpg","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/10\/nhd-comic-3728.jpg","width":1536,"height":1024,"caption":"Editorial comic illustration: CagriSema vs Tirzepatide. Conceptual cover, not experimental imagery."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/cagrisema-tirzepatide-reimagine5-head-to-head-explained\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"CagriSema vs Tirzepatide: What Did REIMAGINE 5 Actually Compare?"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/3728","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=3728"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/3728\/revisions"}],"predecessor-version":[{"id":3732,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/3728\/revisions\/3732"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/3925"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=3728"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=3728"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=3728"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}